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Abstract; 
 
The RUNX1 transcription factor is an important regulator of haematopoiesis and has 
been found to influence gene activity at both the transcriptional and chromatin levels. 
In leukaemia, particularly Acute Myeloid Leukaemia, RUNX1 activity is frequently 
altered by point mutations and chromosomal rearrangements, the most common 
being the t(8;21) translocation that produces a RUNX1-ETO fusion protein. While 
RUNX1 is generally associated with gene activation, RUNX1-ETO mainly acts as a 
transcriptional repressor and its presence is therefore associated with altered 
expression of RUNX1 target genes. 
 
Previous microarray analysis performed in our laboratory identified both the LIFR 
and gp130 genes as novel putative RUNX1 targets. LIFR together with gp130 forms 
a heterodimeric receptor complex that mediates LIF signalling, and in doing so 
controls various cellular processes including cellular development, differentiation 
and inflammatory responses. However, despite their important biological roles little 
is known about regulation of the LIFR and gp130 genes. Bioinformatic analysis 
identified potential RUNX1 binding sites in the promoters of both the LIFR and 
gp130 genes, and this study therefore examined the hypothesis that LIFR and gp130 
are RUNX1 target genes and their altered expression in leukemic cells in which 
RUNX1 is disrupted may therefore contribute to leukaemia.  
 
The LIFR gene is regulated by alternate promoters, with a so called ‘general’ and 
‘placental’ promoter previously described. Analysis of LIFR mRNA across a number 
of cell types demonstrated that activity of the placental promoter is limited to cell 
lines of placental origin, while the general promoter is active in a range of cell types, 
including myeloid cells. This was confirmed by analysis of the chromatin status of 
the two promoters, which found that the general, but not placental promoter is 
assembled into highly acetylated histones in myeloid cells. The expression of the 
gp130 mRNA was detected across all cells lines examined. 
 
vi 
 
Reporter analysis demonstrated that both the placental and general promoters can be 
activated by RUNX1 in placental and myeloid cell lines respectively. In addition, the 
gp130 promoter was activated by RUNX1 in myeloid cell lines. In contrast, RUNX1-
ETO repressed both the LIFR and gp130 promoters in myeloid cells. Further, 
binding of RUNX1 to the endogenous LIFR and gp130 promoters was confirmed by 
chromatin immunoprecipitation, suggesting that the endogenous promoters are 
targeted by RUNX1. In support of this RUNX1 knockdown reduced LIFR and gp130 
expression in myeloid cell lines, and decreased expression of the placental LIFR 
transcript in placental cells.  
 
Put together, the data presented in this thesis demonstrates that RUNX1 regulates 
expression of the LIFR and gp130 promoters, suggesting that activity of the 
LIFR/gp130 receptor complex is likely to be altered in leukaemic cells in which 
RUNX1 is altered.  
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